Clinical Trials
22 trialsNCT07478172 2026-03-17
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
Phase NA Recruiting
NCT00716066 2026-02-27
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT06605612 2025-09-10
FBIndex
LMU Klinikum
Enrolling by invitation
NCT07136844 2025-08-22
Acti-Adult
Centre Hospitalier Universitaire de Liege
Phase NA Recruiting
NCT07075627 2025-08-01
A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)
Addario Lung Cancer Medical Institute
Not yet recruiting
NCT07072676 2025-07-18
Risk of fall
LMU Klinikum
Phase NA Enrolling by invitation
NCT01793168 2025-05-29
CoRDS
Sanford Health
Recruiting
NCT02189720 2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT06441825 2024-06-04
POWER-MG
Heinrich-Heine University, Duesseldorf
Recruiting
NCT05408702 2022-06-07
MYaEX
Institut de Myologie, France
Completed
NCT00872950 2022-04-11
LEMS
Lahey Clinic
Approved for marketing
NCT01825395 2021-10-06
3 4-DAP
University of Colorado, Denver
Approved for marketing
NCT02012933 2019-12-11
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Oregon Health and Science University
No longer available
NCT00704925 2019-10-30
Treatment of Lambert-Eaton Syndrome With 3,4 DAP
University of California, Davis
No longer available
NCT00994916 2019-07-09
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
University of Pittsburgh
No longer available
NCT02970162 2018-12-24
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01377922 2018-01-04
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01511978 2017-07-11
DAPPER
Jacobus Pharmaceutical
Phase 2 Completed
NCT01373333 2016-07-20
34-DAP
The Cleveland Clinic
No longer available
NCT00004832 2015-03-25
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
FDA Office of Orphan Products Development
Phase NA Completed
NCT02124616 2014-04-28
National Registry for Egyptian Pediatric Neuromuscular Diseases
Ain Shams University
Unknown
NCT01378546 2013-07-18
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Columbia University
No longer available